Pharmaceutical Product Development 8-K 2011
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 30, 2011
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
929 North Front Street, Wilmington, North Carolina 28401
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (910) 251-0081
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 5.07. Submission of Matters to a Vote of Security Holders.
On November 30, 2011, Pharmaceutical Product Development, Inc., a North Carolina corporation (the Company), issued a press release announcing that, at a special meeting of shareholders of the Company held on November 30, 2011, its shareholders voted to approve the proposal to approve the Agreement and Plan of Merger (the Merger Agreement), dated October 2, 2011, by and among the Company, Jaguar Merger Sub, Inc. (Merger Sub), a North Carolina corporation and direct wholly-owned subsidiary of Jaguar Holdings, LLC (Parent), a Delaware limited liability company that was formed by affiliates of TC Group, L.L.C. (d/b/a The Carlyle Group) and affiliates of Hellman & Friedman LLC, which provides for the merger (the Merger) of Merger Sub with and into the Company. The shareholders of the Company also voted to approve, on a non-binding advisory basis, the golden parachute compensation that might be received by the Companys named executive officers in connection with the Merger. The final voting results for each proposal are set forth below:
Proposal 1: Adopt the Merger Agreement
Proposal 2: Advisory Vote on Gold Parachute Compensation
A copy of the press release issued by the Company regarding the results of the shareholder vote at the special meeting of shareholders of the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.